


CLAIMS


What is claimed is:

1. A compound, being a compound represented by Formula V, or being a tautomer, stereoisomer, hydrate, solvate or salt of the compound represented by Formula V:



V , wherein

the ring A is selected from , and ;

the ring B is 

;

R^1 is selected from $-CH_3$, $-CHF_2$, and $-CF_3$;

R^2 is selected from C_2-C_6 alkyl, C_3-C_6 cycloalkyl, phenyl, C_2-C_6 halogen-substituted alkyl, C_3-C_6 halogen-substituted cycloalkyl, C_2-C_6 hydroxy-substituted alkyl, C_2-C_6 cyano-substituted alkyl, and $-X-R^{2a}$, where X is selected from sulfur, and -CO-, and R^{2a} is selected from C_1-C_6 alkyl and C_1-C_6 halogen-substituted alkyl;

R^3 is selected from hydrogen, halogen, C_1-C_2 alkyl, C_1-C_2 fluorine-substituted alkyl, and phenyl;

R^4 is selected from hydrogen, halogen, C_1-C_6 alkyl, C_1-C_6 alkoxyl, C_1-C_6 halogen-substituted alkyl, and C_1-C_6 halogen-substituted alkoxyl;


R^5 is selected from hydrogen and halogen;

one of R^{6a} and R^{6b} is hydrogen, and the other one of R^{6a} and R^{6b} is methyl; and

o

M is selected from oxygen, sulfur, and methylene.

2. The compound according to claim 1, being a compound represented by Formula II, or being a tautomer, stereoisomer, hydrate, solvate or salt of the compound represented by Formula II:



II , wherein

R^1 is selected from $-CH_3$, $-CHF_2$, and $-CF_3$, and preferably, R^1 is $-CHF_2$;

R^2 is selected from ethyl, propyl, isopropyl, n-butyl, isobutyl, tert-butyl, fluoro-substituted ethyl, fluoro-substituted propyl, fluoro-substituted isopropyl, fluoro-substituted butyl, fluoro-substituted isobutyl, hydroxyethyl, hydroxyisopropyl, cyanoethyl, phenyl, and $-X-R^{2a}$, where X is selected from sulfur, and -CO-, and R^{2a} is selected from methyl, ethyl, fluoro-substituted methyl, and fluoro-substituted ethyl;

R^3 is selected from hydrogen, fluorine, chlorine, methyl, ethyl, fluoro-substituted methyl, fluoro-substituted ethyl, and phenyl;


R^4 is selected from hydrogen, fluorine, chlorine, methyl, ethyl, fluoro-substituted methyl, and fluoro-substituted ethyl;

R^5 is selected from hydrogen, fluorine, and chlorine; and

M is selected from oxygen, sulfur, and methylene.

3. A compound, being a compound represented by Formula I, or being a tautomer, stereoisomer, hydrate, solvate or salt of the compound represented by Formula I:

o



I , wherein

R^1 is selected from -CH_3, -CHF_2, and -CF_3;

R^2 is selected from C_2-C_6 alkyl, C_3-C_6 cycloalkyl, C_2-C_6 halogen-substituted alkyl, and C_3-C_6 halogen-substituted cycloalkyl;

R^3 is selected from hydrogen, halogen, C_1-C_2 alkyl, and C_1-C_2 fluorine-substituted alkyl;

R^4 is selected from hydrogen, halogen, C_1-C_6 alkyl, C_1-C_6 alkoxyl, C_1-C_6 halogen-substituted alkyl, and C_1-C_6 halogen-substituted alkoxyl.


4. The compound according to claim 3, wherein

R^2 is selected from C_2-C_3 alkyl, C_3-C_6 cycloalkyl, C_2-C_3 fluorine-substituted alkyl, and C_3-C_6 fluorine-substituted cycloalkyl, and preferably, R^2 is selected from -CH_2CH_3, -$CH(CH_3)_2$, cyclopropyl, -CF_2CH_3, and -CH_2CF_3;


R^3 is selected from hydrogen, fluorine, and chlorine;

R^4 is selected from hydrogen, fluorine, chlorine, C_1-C_4 alkyl, C_1-C_4 alkoxyl, C_1-C_4 fluorine- or chlorine-substituted alkyl, and C_1-C_4 fluorine- or chlorine-substituted alkoxyl, and preferably, R^4 is selected from hydrogen, fluorine, and chlorine.


5. A compound, being any one of the following compounds, or being a tautomer, stereoisomer, hydrate, solvate or pharmaceutically acceptable salt of any one of the following compounds:



I-1




I-2




I-3


o




I-4




I-5




I-6




I-7




I-8




I-9




I-10




I-11




I-12




I-13




I-14



I-15




I-16




I-17


o




I-21




I-22




I-23




I-24




I-27



I-29




I-30



I-33

o



I-39 .

6. A pharmaceutical composition, comprising:

a pharmaceutically acceptable excipient; and

the compound according to any one of claims 1 to 5.

7. Use of the compound according to any one of claims 1 to 5 or the pharmaceutical composition according to claim 6 in the preparation of a medicament for the treatment or prevention of at least one disease selected from the group consisting of an inflammatory disease, a pain, a cancer, a metabolic disease, and a urinary system disease;

wherein the pain is selected from osteoarthritis pain and endometriosis-induced pain, and

wherein the urinary system disease is overactive bladder.

8. The use according to claim 7, wherein the inflammatory disease is selected from arthritis and rheumatoid arthritis.

9. The use according to claim 7, wherein the medicament is adapted to be administered in combination with a radiation therapy and/or an antibody therapy, the antibody therapy being selected from the group consisting of a CTLA4 antibody therapy, a PDL1 antibody therapy, a PD1 antibody therapy, and combinations thereof.

10. The use according to claim 7, wherein the cancer is selected from solid cancers, preferably from breast cancer, cervical cancer, colorectal cancer, endometrial cancer, glioblastoma, head and neck cancer, kidney cancer, liver cancer, lung cancer, medulloblastoma, ovarian cancer, pancreatic cancer, prostate cancer, skin cancer, and urethral cancer.

11. The use according to claim 7, wherein the metabolic disease is diabetes.

12. The compound according to any one of claims 1 to 5 or the pharmaceutical

o

composition according to claim 6 for use in therapy a disease selected from an inflammatory disease, a pain, a cancer, a metabolic disease, and a urinary system disease;

wherein the pain is selected from osteoarthritis pain and endometriosis-induced pain, and

wherein the urinary system disease is overactive bladder.

13. The compound or the pharmaceutical composition for use according to claim 12, wherein the inflammatory disease is selected from arthritis and rheumatoid arthritis.

14. The compound or the pharmaceutical composition for use according to claim 12, wherein the cancer is selected from solid cancers, preferably from breast cancer, cervical cancer, colorectal cancer, endometrial cancer, glioblastoma, head and neck cancer, kidney cancer, liver cancer, lung cancer, medulloblastoma, ovarian cancer, pancreatic cancer, prostate cancer, skin cancer, and urethral cancer.

15. The compound or the pharmaceutical composition for use according to claim 12, wherein the compound or the pharmaceutical composition is administered in combination with a radiation therapy and/or an antibody therapy, the antibody therapy being selected from the group consisting of a CTLA4 antibody therapy, a PDL1 antibody therapy, a PD1 antibody therapy, and combinations thereof.

16. The compound or the pharmaceutical composition for use according to claim 12, wherein the metabolic disease is diabetes.

o